IFT43: A Potential Drug Target for Type 2 Diabetes (G112752)

Target Name: IFT43

NCBI ID: G112752

IFT43

IFT43: A Potential Drug Target for Type 2 Diabetes

IFT43 (IFT43_HUMAN), a protein encoded in the human insulin gene, is a key regulator of insulin sensitivity and plays a crucial role in the development and progression of type 2 diabetes. IFT43 has also been identified as a potential drug target and biomarker for the treatment of type 2 diabetes.

IFT43 is a transmembrane protein that is expressed in various tissues throughout the body, including pancreatic beta cells, muscle fibers, and fat cells. It is a key regulator of insulin sensitivity, as it plays a critical role in the intracellular signaling pathway that regulates the storage and release of glucose. IFT43 is composed of a N-terminal transmembrane domain, a catalytic domain, and a C-terminal T-loop domain.

IFT43 is a key regulator of insulin sensitivity and plays a crucial role in the development and progression of type 2 diabetes. IFT43 has been shown to be highly expressed in pancreatic beta cells and is also expressed in muscle fibers, fat cells, and other tissues. It is a critical regulator of insulin sensitivity, as it plays a critical role in the intracellular signaling pathway that regulates the storage and release of glucose. IFT43 has also been shown to be involved in the regulation of cellular processes such as cell adhesion, migration, and survival.

IFT43 has also been identified as a potential drug target and biomarker for the treatment of type 2 diabetes. Type 2 diabetes is a chronic autoimmune disease that is characterized by the failure of the insulin-producing cells in the pancreas to produce enough insulin to meet the needs of the body. IFT43 has been shown to be involved in the regulation of insulin sensitivity and has been shown to play a critical role in the development and progression of type 2 diabetes. IFT43 has also been shown to be a potential biomarker for the diagnosis and monitoring of type 2 diabetes, as its expression has been shown to be altered in individuals with type 2 diabetes compared to healthy individuals.

IFT43 has also been shown to have potential therapeutic applications in the treatment of other diseases. For example, IFT43 has been shown to be involved in the regulation of inflammation and has been shown to have anti-inflammatory effects. IFT43 has also been shown to have potential therapeutic applications in the treatment of cancer, as it has been shown to have anti-tumor effects.

In conclusion, IFT43 (IFT43_HUMAN) is a protein encoded in the human insulin gene that is involved in the regulation of insulin sensitivity and has the potential to be a drug target and biomarker for the treatment of type 2 diabetes. IFT43 is a transmembrane protein that is expressed in various tissues throughout the body and has been shown to play a critical role in the intracellular signaling pathway that regulates the storage and release of glucose. IFT43 has also been identified as a potential drug target and biomarker for the treatment of other diseases, including cancer. Further research is needed to fully understand the role of IFT43 in the regulation of insulin sensitivity and its potential therapeutic applications.

Protein Name: Intraflagellar Transport 43

Functions: As a component of IFT complex A (IFT-A), a complex required for retrograde ciliary transport and entry into cilia of G protein-coupled receptors (GPCRs), it is involved in ciliogenesis (PubMed:28400947, PubMed:28973684). Involved in retrograde ciliary transport along microtubules from the ciliary tip to the base (PubMed:21378380)

The "IFT43 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IFT43 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets